NCT06001788 2025-12-03
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1 Recruiting
Clinical Trials
7 trialsNCT05963217 2025-07-02
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
University Health Network, Toronto
Phase 1 Recruiting
NCT04310592 2024-12-12
CYNK001AML01
Celularity Incorporated
Phase 1 Terminated
NCT03761069 2022-02-02
Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias
PTC Therapeutics
Phase 1 Terminated
NCT03722186 2021-03-22
Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Suspended
NCT00878189 2019-11-12
A Trial In Patients With Advanced Cancer And Leukemia
Pfizer
Phase 1 Completed
NCT03114670 2017-06-14
Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT
Affiliated Hospital to Academy of Military Medical Sciences
Phase 1 Unknown